Shilpa Medicare Secures SEC-CDSCO Nod for Nor-Ursodeoxycholic Acid Tablets, Eyes Market Launch for NASH
NAFLD, the most prevalent liver disease, affects approximately 25% of the global population (1.2 billion people), including 188 million in India. Left untreated, NAFLD can progress to non-alcoholic steatohepatitis (NASH), a severe and potentially fatal condition.
Shilpa Medicare Ltd. had earlier completed phase-3 clinical studies of this novel product SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets - and presented the results of the trial titled, 'A phase - III, Randomized, Double- Blind, placebo controlled, multicenter, Parallel group study', to evaluate the safety and efficacy of Nor-Ursodeoxycholic Acid 500 mg in patients suffering from Non-alcoholic Fatty Liver Disease to the SEC.
The trial met all primary efficacy endpoints, demonstrating a significant improvement in fatty liver stage. Key findings include:
Liver Fibrosis Reversal: 83.3% of participants showed fibrosis reversal, with stabilization in the rest.
ALT Normalization: Elevated alanine transaminase (ALT) levels, a key NAFLD marker, normalized in ~90% of participants within 12 weeks.
These results position Nor UDCA as a breakthrough therapy for NAFLD, offering advantages over conventional UDCA, including enhanced choleretic effect, resistance to amidation, anti-inflammatory properties, and fibrosis reduction.
Commenting on the development, Mr. Vishnukant Bhutada – Managing Director, Shilpa Medicare Limited, said, 'We are very pleased with this approval from SEC and hope to get the marketing approval soon. We are committed to working closely with regulatory authorities to bring this innovative treatment to patients as quickly as possible and are hopeful of launching it in India in the coming financial year. This NCE molecule approval exemplifies the true spirit of Shilpa, 'Innovating for affordable healthcare', keeping in mind the unmet needs of a large patient pool. Based on the approval in India, we plan to reach out to Global regulatory authorities to seek scientific advice for introduction of this novel product internationally.'
Founded in 1987, Shilpa Medicare offers APIs, Formulations, and Biologics, with facilities approved by major regulatory agencies. The company is also recognized for providing complete turnkey CDMO solutions for clients globally.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Implantica publishes Interim Report January - June 2025 (Q2)
VADUZ, Liechtenstein, Aug. 14, 2025 /PRNewswire/ -- Transforming Clinical Excellence of RefluxStop® into Strategic Market Momentum Significant events in the second quarter of 2025 FDA PMA Submission Completed - Submitted third and final module of the U.S. FDA pre-market approval (PMA) application for RefluxStop®, including responses to questions on the second module; Feedback on module 3 expected in the near-term Produced and completed initial testing on new multi-cavity production tool for RefluxStop® to support launch of manufacturing in U.S. and manage ramp-up of U.S. production (pending FDA approval) Additional preparations for U.S. market launch (pending FDA approval) included U.S. payer and reimbursement activities, finalizing new production facility of RefluxStop® in U.S. and launching our RCT (randomized clinical trial), as a heavyweight cornerstone in building global leadership in acid reflux care Positive NICE Guidance in the UK - UK's National Institute for Health and Care Excellence (NICE) issued positive guidance for the use of RefluxStop® in NHS hospitals for patients with ineffective esophageal motility (IOM/IEM), potentially transforming treatment access for millions and influencing global policy Significant events after the end of the period Landmark 5-Year Clinical Study Results - Two peer-reviewed articles were published in Surgical Endoscopy on our pivotal study results; one publication confirmed outstanding long-term safety and effectiveness outcomes, and the second publication highlighted RefluxStop®'s excellent outcomes in food passageway-related sequelae, which is common in standard of care Randomized Clinical Trial (RCT) Launch - First RCT comparing RefluxStop® with Nissen fundoplication; patient recruitment underway accumulating patients across participating hospitals. While this trial preparation led to a 20% year-on-year revenue decline for Q2, the impact is expected to ease once study recruitment stabilizes Spanish Market Expansion - Three new hospitals added, totaling 19 centers offering RefluxStop® in Spain, with a healthcare sytem receptive for new and better patient care, which is a fantastic launch since 2023 First UK National Users Meeting - Convened 21 top anti-reflux experts to discuss real-world results, operating technique and the opportunities arising from NICE's positive recommendation Financial summary second quarter 2025 Net sales decreased 22% to TEUR 433 (554) due to the launch of the randomized clinical trial with surgeons accumulating patients for the trial. Adjusted gross margin amounted to 90% (91%). Operating loss (EBIT) decreased to TEUR 4,525 (5,869). Loss after tax decreased to TEUR 5,448 (6,431). Basic and diluted loss per Class A share amounted to EUR 0.08 (0.09). Cash and short-term investments as at the end of the period of MEUR 56.3. First six months Net sales increased 2% to TEUR 1,178 (1,150). Adjusted gross margin amounted to 94% (91%). Operating loss (EBIT) decreased to TEUR 8,698 (12,956). Loss after tax decreased to TEUR 8,212 (9,903). Basic and diluted loss per Class A share amounted to EUR 0.12 (0.14). Telephone conference Implantica will hold a teleconference on 14 August 2025 at 15:00 (CEST) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: Webcast If you wish to participate via webcast, please use the following link: Dial-in Dial-in numbers to the teleconference will be received by registering on the link below. After the registration, you will be provided phone numbers and a conference ID to access the conference. For further information, please contact:Nicole Pehrsson, Chief Corporate Affairs OfficerTelephone (CH): +41 (0)79 335 09 Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company's Certified Adviser is FNCA Sweden AB, info@ This information is information that Implantica AG is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-08-14 08:00 CEST. About Implantica: Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop®, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit for further information. This information was brought to you by Cision The following files are available for download: Implantica Q2 2025_ENG Implantica publishes Interim Report Jan - Jun 2025 Q2 View original content:
Yahoo
7 hours ago
- Yahoo
Shilpa Medicare's NorUDCA Makes History as First Approved NAFLD Therapy Worldwide
Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty Liver Disease (NAFLD) NAFLD affects 1 in 4 people globally (1.2 billion), with 188 million patients in India—most undiagnosed until irreversible damage occurs. A Breakthrough in Liver Health: NorUDCA delivers a novel dual-action mechanism, combining anti-inflammatory benefits with enhanced bile acid regulation. This innovative therapy promises to halt the progression of NAFLD to severe liver conditions such as NASH, cirrhosis, and liver failure. Clinically Proven and Safe: Robust clinical trials demonstrate NorUDCA's significant superiority over placebo in efficacy, with an excellent safety profile and no major adverse events reported RAICHUR, India, Aug. 14, 2025 /PRNewswire/ -- In a landmark moment for global hepatology and Indian pharmaceutical innovation, Shilpa Medicare Limited (BSE: 530661) (NSE: SHILPAMED) has secured the world's first regulatory approval from India's Central Drugs Standard Control Organization (CDSCO) for Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg, the first-ever approved therapy targeting NAFLD. Mr. Vishnukant Bhutada, Managing Director, Shilpa Medicare, hailed the approval as a "transformational leap": "Receiving approval for NorUDCA marks a transformational leap—not only for Shilpa Medicare but for millions silently suffering from liver disease. We are honored to be the first company globally to bring this innovative therapy to patients, reflecting our unwavering commitment to pioneering healthcare solutions and expanding access to life-changing treatments across India and beyond. We are excited to launch NorUDCA in India immediately and are actively pursuing approvals worldwide to ensure this vital therapy reaches patients everywhere in need." Shilpa Medicare is committed to rapidly commercializing NorUDCA in India and pursuing international regulatory pathways, aiming to bring this life-altering treatment to patients on a global scale About Shilpa Medicare Limited: Shilpa Medicare Limited is a fully integrated pharmaceutical group specializing in innovative Oncology and Non-Oncology APIs, Peptides, Polymers, New Biological Entities and differentiated finished dosage formulations such as Orally Dispersible Films and Transdermal Patches. The company offers end-to-end CDMO services to global pharmaceutical partners, supported by four advanced R&D centers and seven manufacturing facilities, consistently driving innovation and quality in healthcare. View original content: SOURCE Shilpa Medicare Limited
Yahoo
9 hours ago
- Yahoo
Global Digital Therapeutics Market Experiencing Rapid Growth at a CAGR of ~28% by 2032 Amid Rising Demand for Personalized Healthcare
The digital therapeutics market is experiencing rapid growth, driven by rising demand for personalized, evidence-based digital health interventions. Increasing prevalence of chronic conditions, mental health issues, and the global push toward remote healthcare are key factors fueling adoption. Regulatory support and integration with traditional healthcare systems are further validating the efficacy of DTx solutions. LAS VEGAS, Aug. 13, 2025 /PRNewswire/ -- DelveInsight's Digital Therapeutics Market Insights report provides the current and forecast market analysis, individual leading digital therapeutics companies' market shares, challenges, digital therapeutics market drivers, barriers, trends, and key digital therapeutics companies such as Limbix Health, Inc., GAIA AG, BigHealth, DarioHealth Corp, HYGIEIA, Akili, Inc., Pear Therapeutics (US), Inc., and others in the market. Digital Therapeutics Overview Digital therapeutics are evidence-based therapeutic interventions delivered through software programs to prevent, manage, or treat medical disorders and diseases. Unlike general wellness apps, digital therapeutics undergo rigorous clinical validation and regulatory review to demonstrate their efficacy, much like traditional pharmaceuticals. These interventions are often used in areas like mental health, chronic disease management (such as diabetes, hypertension, or asthma), and substance use disorders. Delivered via smartphones, tablets, or other digital devices, DTx can be used independently or alongside traditional treatments, offering a scalable, accessible, and often more engaging method of care. One of the key strengths of digital therapeutics is their ability to personalize treatment and provide real-time feedback. By leveraging data analytics, machine learning, and behavioral science, DTx platforms can adapt to individual user needs and track progress continuously. This not only enhances patient engagement but also empowers clinicians with insights to make better-informed decisions. As healthcare systems worldwide face rising costs and increasing demand for chronic care, digital therapeutics offer a promising avenue to improve outcomes, reduce burden on clinical resources, and extend care to underserved populations. Digital Therapeutics Regional Market Insights The global digital therapeutics market is experiencing rapid growth, with notable regional differences driven by healthcare infrastructure, regulatory environments, and technological adoption. North America remains the dominant market, primarily due to strong healthcare reimbursement frameworks, a high prevalence of chronic diseases, and robust digital health ecosystems. The US leads in regulatory clarity, with the FDA approving multiple DTx solutions for conditions like diabetes, insomnia, and mental health. The region also benefits from significant investment activity and partnerships between DTx developers and major pharmaceutical companies. In contrast, Europe is advancing steadily, aided by supportive government initiatives, especially in Germany through its DiGA framework, which allows prescription and reimbursement of certified DTx apps. Scandinavian countries and the UK are also showing strong adoption due to digital-first healthcare strategies. Meanwhile, the Asia-Pacific region is poised for the fastest growth, led by Japan, South Korea, and increasingly, China and India. Factors such as rising smartphone penetration, aging populations, and increasing chronic disease burden are catalyzing adoption. However, regulatory uncertainty and reimbursement limitations continue to pose challenges across emerging markets, requiring targeted policy and infrastructure development to unlock full potential. To know more about why North America is leading the market growth in the digital therapeutics market, get a snapshot of the Digital Therapeutics Market Report Recent Developments in the Digital Therapeutics Market In April 2025, Click Therapeutics, Inc., a pioneer in prescription digital therapeutics and software-enhanced drug therapies, received FDA marketing authorization for the first prescription digital therapeutic designed to prevent episodic migraine. To read more about digital therapeutics for mental health, get a snapshot of the key highlights entailed in the Digital Therapeutics in Mental Health Key Players in the Digital Therapeutics Market The digital therapeutics market has seen a surge in innovation and investment, with several key players emerging as leaders due to their robust pipelines, strong clinical evidence, and strategic partnerships. Companies like Limbix Health, Inc., GAIA AG, BigHealth, DarioHealth Corp, HYGIEIA, Akili, Inc., Pear Therapeutics (US), Inc., CANARY HEALTH, Noom, Inc., Omada Health Inc., Welldoc, Inc., 2Morrow, Inc., ResMed, Teladoc Health, Inc., Fitbit Health Solutions, Huma, and others have pioneered prescription digital therapeutics across areas such as mental health, ADHD, and chronic disease management. Large tech and pharma companies are also entering the space, accelerating market maturity and broadening DTx applications. These players are not only shaping the competitive landscape but are also influencing regulatory pathways, reimbursement models, and global adoption trends in the digital health ecosystem. Which MedTech key players in the digital therapeutics diabetes are set to emerge as the trendsetter explore @ Digital Therapeutics Behavioral Health Digital Therapeutics Market Key Factor Analysis Digital Therapeutics Market Drivers The growth of the digital therapeutics market is being driven by several key factors. There is a rising demand for remote patient monitoring and mobile health applications, which enable convenient, real-time health management and improve patient engagement outside traditional clinical settings. This trend is further fueled by the increasing prevalence of chronic diseases such as diabetes, cardiovascular disorders, and mental health conditions, which require long-term and continuous care. Additionally, rapid advancements in digital healthcare technologies, including the integration of the Internet of Things (IoT), artificial intelligence (AI), and data analytics, are enhancing the effectiveness and personalization of digital therapeutic solutions, thereby accelerating market adoption. Digital Therapeutics Market Restraints and Challenges The digital therapeutics market faces notable restraints and challenges, primarily revolving around cybersecurity, privacy concerns, and unstable payment models. As digital health solutions increasingly rely on the collection and analysis of sensitive patient data, concerns about data breaches, unauthorized access, and misuse of personal health information pose significant barriers to widespread adoption. Ensuring robust cybersecurity measures and maintaining user trust are critical for the success of these technologies. Additionally, the market is hindered by unstable and evolving payment and reimbursement models. The lack of standardized frameworks for coverage and reimbursement from insurers and healthcare systems creates uncertainty for providers and developers, limiting investment and scalability in the sector. These challenges must be addressed to unlock the full potential of digital therapeutics in modern healthcare. Digital Therapeutics Market Opportunities The digital therapeutics market is witnessing significant growth opportunities, driven by increasing supportive initiatives and strategic alliances among key industry players. Government bodies, healthcare organizations, and regulatory authorities are actively promoting the adoption of digital health solutions through funding, policy support, and streamlined approval processes. At the same time, strategic collaborations between pharmaceutical companies, technology firms, and digital health startups are accelerating product development, expanding market reach, and enhancing therapeutic outcomes. These partnerships are fostering innovation, improving patient engagement, and paving the way for scalable and evidence-based digital interventions across a wide range of chronic and behavioral health conditions. Get a sneak peek at the digital therapeutics FDA approval @ FDA Approved Digital Therapeutics Report Metrics Details Coverage Global Study Period 2022–2032 Digital Therapeutics Market CAGR ~28% Key Digital Therapeutics Companies Limbix Health, Inc., GAIA AG, BigHealth, DarioHealth Corp, HYGIEIA, Akili, Inc., Pear Therapeutics (US), Inc., CANARY HEALTH, Noom, Inc., Omada Health Inc., Welldoc, Inc., 2Morrow, Inc., ResMed, Teladoc Health, Inc., Fitbit Health Solutions, Huma, and others Digital Therapeutics Market Assessment Digital Therapeutics Market Segmentation Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Interested in knowing the digital therapeutics services? Click to get a snapshot of the Digital Therapeutics Platform Table of Contents 1 Digital Therapeutics Market Report Introduction 2 Digital Therapeutics Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 Digital Therapeutics Market Key Factors Analysis 6 Digital Therapeutics Market Porter's Five Forces Analysis 7 Digital Therapeutics Market Layout 8 Digital Therapeutics Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Related Reports Digital Health Market Digital Health Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key digital health companies, including Siemens Healthcare Private Limited, Cisco Systems, Inc., Oracle Cerner, Altera Digital Health Inc., Telefonica, Epic, AT&T, AmerisourceBergen, Candela Corporation., GE Healthcare, Samsung Health, MCKESSON CORPORATION, AliveCor, Inc., Acurable, Amwell, OMRON Healthcare, Inc., Apple Inc., SoftServe, AirStrip Technologies, Inc, Epic Systems Corporation, among others. Telemedicine Service Market Telemedicine Service Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key telemedicine service companies, including Teladoc Health, Inc., MEDICI, American Well, Doximity, Inc., Practo, DocOnline, MeMD®, iCliniq, HealthTap, Inc., WELL Health Technologies Corp., Vesta Teleradiology, Samsung Health U.S, Rudolf Riester GmbH, SHL Telemedicine, Array Behavioral Care, SOC Telemed, Heidelberg Medical Consultancy & Health Tourism Pvt. Ltd., First Derm, DirectDerm, among others. Telehealth Market Telehealth Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key telehealth companies, including Teladoc Health, Inc., Siemens, Cisco Systems, Inc., Koninklijke Philips N.V., IBM Corporation, Medtronic, Cerner Corporation, American Well, AMD Global Telemedicine, Joerns Healthcare., GlobalMed, OncoHealth, Allscripts Healthcare, LLC, Derma2go, SOCTelemed, Inc., Honeywell International Inc., Plantronics, Inc., Carium., Emmaus Life Sciences, Inc., Practo, among others. Healthcare Cybersecurity Market Healthcare Cybersecurity Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key healthcare cybersecurity companies, including IBM Corporation, Barracuda Networks, Inc., Forcepoint, Cisco Systems Inc., CrowdStrike Holdings, Inc., Happiest Minds, Palo Alto Networks, Availity, LLC., SentinelOne, HALOCK, Cynerio, KUDELSKI SA, Sophos Ltd., iConnect IT Business Solutions DMCC, illume intelligence, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact UsShruti Thakur info@ +14699457679https:// Logo: View original content: SOURCE DelveInsight Business Research, LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
